FOLD

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotechnology company founded in 2002 and headquartered in Philadelphia, Pennsylvania. The company went public in 2007 and specializes in developing and commercializing precision medicines for rare genetic diseases. Amicus has evolved from a research-stage company into a commercial-stage biopharmaceutical enterprise with two approved therapies generating over $500 million in annual revenue. The company focuses primarily on lysosomal storage disorders, a group of inherited metabolic diseases caused by enzyme deficiencies that affect cellular function.